OIG to CMS: 51 drugs may be overpriced: CMS disputes OIG's calculations, however.(Office of Inspector General to Centers for Medicare & Medicaid Services)(Brief article)

Publication: Medicine & Health

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2006 Eli Research, Inc.

A few dozen Part B drugs could be facing steep drops to their already-low reimbursements soon. The law gives the Centers for Medicare & Medicaid Services the authority to slash drug payments if the average sales price (ASP) is at least 5 percent higher than the average price the...

Read the full article for free courtesy of your local library.